Delanzomib(CEP-18770)是口服活性的蛋白酶体糜蛋白酶样活性抑制剂,能下调核内NF-kappaB活性。
CEP-18770 (Delanzomib) is an orally active inhibitor of the chymotrypsin-like activity of proteasome with IC50 of 3.8 nM, with only marginal inhibition of the tryptic and peptidylglutamyl activities of the proteosome. Phase 1/2.
0-100 nM
1.5到4mg/kg,每周2次,持续4周 静脉注射
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Piva R,et al. Blood. 2008,111(5),2765-2775.
[2] Seavey MM, et al. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol. 2012 Jan;12(1):257-70.
[3] Sanchez E, et al. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br J Haematol. 2010 Feb;148(4):569-81.
分子式 C21H28BN3O5 |
分子量 413.28 |
CAS号 847499-27-8 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 85 mg/mL |
Water <1 mg/mL |
Ethanol 85 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT01023880 | Multiple Myeloma | Drug: CEP-18770 | Cephalon|Teva Pharmaceutical Industries | Phase 1|Phase 2 | 2010-01-01 | 2016-03-10 |
NCT01348919 | Multiple Myeloma | Drug: CEP-18770|Drug: Lenalidomide|Drug: Dexamethasone | Cephalon|Teva Pharmaceutical Industries | Phase 1|Phase 2 | 2011-08-01 | 2016-07-19 |
NCT00572637 | Solid Tumors|Lymphoma, Non-Hodgkin | Drug: CEP-18770 | Ethical Oncology Science | Phase 1 | 2007-11-01 | 2010-05-19 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们